While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...

Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement ...

The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment ...

Roche announces positive results from EMBARK phase III study of Elevidys in ambulatory individuals with DMD: Basel Tuesday, January 28, 2025, 11:00 Hrs [IST] Roche announced posit ...

Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...

Roche has reported positive topline outcomes from the second year of the multinational Phase III EMBARK trial of Elevidys ...

Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene ...

Despite mixed results using gene therapies to treat Duchenne muscular dystrophy, drug developers are pushing ahead with the ...

Analyst Gil Blum from Needham maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) and keeping the price target at ...

Sarepta (SRPT) announced topline results from Part 2 of EMBARK, a global, randomized, double-blind, placebo-controlled, Phase 3 clinical study ...

Top-line Phase 3 trial data show ambulatory boys with Duchenne continued with motor improvements two years after a single ...

The US Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to NS-051/NCNP-04, which is ...